Amoy Diagnostics

Executive Summary

Amoy Diagnostics (AmoyDx) is a leading Chinese molecular diagnostics company specializing in precision oncology. Founded in 2008 and headquartered in Xiamen, the company develops and commercializes PCR- and NGS-based companion diagnostic (CDx) kits, primarily for lung cancer and hereditary cancers. Its proprietary technologies—ADx-ARMS/Super-ARMS for PCR and HANDLE/ddCapture for NGS—enable sensitive, accessible mutation detection, positioning AmoyDx as a key player in China's growing precision medicine market. The company operates at a commercial stage with 200–500 employees and serves as a critical partner for pharmaceutical firms developing targeted therapies. Despite being privately held and having limited public financial disclosures, AmoyDx's established technology platform and regulatory expertise in the Chinese market provide a competitive moat. Looking ahead, AmoyDx is poised to benefit from expanding CDx requirements for new oncology drugs in China and increasing adoption of NGS-based liquid biopsies. The company's strong focus on lung cancer aligns with high incidence rates in China, while ongoing partnerships with global pharma companies for drug-diagnostic co-development could drive revenue growth. However, risks include regulatory dependency on NMPA approvals and competition from both domestic and international molecular diagnostics firms. Overall, AmoyDx represents a solid but speculative investment opportunity in the Chinese precision oncology diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026NMPA approval of new CDx kit for a targeted therapy70% success
• Q2 2026Strategic partnership with a major pharma for companion diagnostic development60% success
• Q3 2026Launch of expanded NGS panel for multiple cancer types75% success